Nuclera, a Cambridge- and Boston-based biotechnology company focused on accelerating drug discovery through rapid access to functional proteins, has secured an additional $12 million in Series C funding.
Your go-to source for the latest Startup developments.
Would you like us to send you the latest news from the startup world?